In vitro and in vivo activity of antisense inhibitors of ras: Potential for clinical development

被引：0
|
作者：
Cowsert, LM
机构：
来源：
ANTI-CANCER DRUG DESIGN | 1997年 / 12卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：359 / 371
页数：13
相关论文
共 50 条
  • [31] Phenol-derived CVFM analog inhibitors of Ras Farnesyltransferase possessing cellular in vitro activity
    Caliendo, G
    Fiorino, F
    Grieco, P
    Perissutti, E
    Ramunno, A
    Santagada, V
    Albrizio, S
    Califano, D
    Giuliano, A
    Santelli, G
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 1998, 33 (09) : 725 - 732
  • [32] Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase Inhibitors
    Burger, Matthew T.
    Han, Wooseok
    Lan, Jiong
    Nishiguchi, Gisele
    Bellamacina, Cornelia
    Lindval, Mika
    Atallah, Gordana
    Ding, Yu
    Mathur, Michelle
    McBride, Chris
    Beans, Elizabeth L.
    Muller, Kristine
    Tamez, Victoriano
    Zhang, Yanchen
    Huh, Kay
    Feucht, Paul
    Zavorotinskaya, Tatiana
    Dai, Yumin
    Holash, Jocelyn
    Castillo, Joseph
    Langowski, John
    Wang, Yingyun
    Chen, Min Y.
    Garcia, Pablo D.
    ACS MEDICINAL CHEMISTRY LETTERS, 2013, 4 (12): : 1193 - 1197
  • [33] Colorectal Carcinogenesis: Connecting K-RAS-Induced Transformation and CREB Activity In Vitro and In Vivo
    Steven, Andre
    Heiduk, Max
    Recktenwald, Christian V.
    Hiebl, Bernhard
    Wickenhauser, Claudia
    Massa, Chiara
    Seliger, Barbara
    MOLECULAR CANCER RESEARCH, 2015, 13 (08) : 1248 - 1262
  • [34] Development of triazolothiadiazine derivatives as highly potent tubulin polymerization inhibitors: Structure-activity relationship, in vitro and in vivo study
    Ma, Weifeng
    Chen, Peng
    Huo, Xiansen
    Ma, Yufeng
    Li, Yanhong
    Diao, Pengcheng
    Yang, Fang
    Zheng, Shengquan
    Hu, Mengjin
    You, Wenwei
    Zhao, Peiliang
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 208
  • [35] FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma
    King, Gentry
    Javle, Milind
    CURRENT ONCOLOGY REPORTS, 2021, 23 (09)
  • [36] FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma
    Gentry King
    Milind Javle
    Current Oncology Reports, 2021, 23
  • [37] Evaluation of the In vitro and In vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma
    Dalgard, Clifton Lee
    Van Quill, Kurtis R.
    O'Brien, Joan M.
    CLINICAL CANCER RESEARCH, 2008, 14 (10) : 3113 - 3123
  • [38] Macrocyclic Peptidomimetic Plasmepsin X Inhibitors with Potent In Vitro and In Vivo Antimalarial Activity
    Kovada, Vadims
    Withers-Martinez, Chrislaine
    Bobrovs, Raitis
    Cerule, Helena
    Liepins, Edgars
    Grinberga, Solveiga
    Hackett, Fiona
    Collins, Christine R. R.
    Kreicberga, Agrita
    Jimenez-Diaz, Maria Belen
    Angulo-Barturen, Inigo
    Rasina, Dace
    Suna, Edgars
    Jaudzems, Kristaps
    Blackman, Michael J.
    Jirgensons, Aigars
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (15) : 10658 - 10680
  • [39] Novel cinnamohydroxamic acid derivatives as HDAC inhibitors with anticancer activity in vitro and in vivo
    Wang, Lihui
    Bao, Xuefei
    Yang, Jingyu
    Li, Huahuan
    Zhou, Qifan
    Jiang, Xiaorui
    Li, Meng
    Liu, Xing
    Yuan, Xiangzhong
    Sun, Yuhong
    Chen, Junli
    Zhang, Jingyuan
    Chen, Guoliang
    Wu, Chunfu
    CHEMICO-BIOLOGICAL INTERACTIONS, 2016, 249 : 64 - 70
  • [40] Synthesis, in vitro and in vivo activity of benzophenone-based inhibitors or steroid sulfatase
    Hejaz, HAM
    Woo, LWL
    Purohit, A
    Reed, MJ
    Potter, BVL
    BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (10) : 2759 - 2772
12345